1 Min Read
Jan 17 (Reuters) - Amgen Inc:
* OVERALL SURVIVAL ANALYSIS FROM KYPROLIS® (CARFILZOMIB) PHASE 3 ASPIRE TRIAL PUBLISHED IN THE JOURNAL OF CLINICAL ONCOLOGY Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.